Welcome to LookChem.com Sign In|Join Free

CAS

  • or

50-14-6

Post Buying Request

50-14-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • High quality injection grade Vitamin D2 powder with best price

    Cas No: 50-14-6

  • USD $ 40.0-50.0 / Kilogram

  • 1 Kilogram

  • 33 Metric Ton/Month

  • Kono Chem Co.,Ltd
  • Contact Supplier

50-14-6 Usage

Description

Different sources of media describe the Description of 50-14-6 differently. You can refer to the following data:
1. Ergocalciferol, also under the name vitamin D2, is a type of vitamin D found in plants and yeast. It has no antirachitic activity. It helps the body to absorb calcium and phosphorus. It is used as a dietary supplement. It is used in the treatment of hypoparathyroidism (a condition in which not enough parathyroid hormone can be produced by the body), refractory rickets (softening and weakening of bones that does not respond to treatment, it is also known as vitamin D resistant rickets), and familial hypophosphatemia (rickets or osteomalacia caused by an inherited condition with a decreased ability to break down vitamin D in the body). Ergocalciferol is also used as a rodenticide.
2. Vitamin D aids in the absorption of calcium and has central roles in bone formation and maintenance, hypertension, cancer and immunity. Vitamin D may be obtained from many dietary sources, including eggs and fish, and is synthesized in the skin by the conversion of 7-dehydrocholesterol to vitamin D3 by ultraviolet light. Vitamin D2 is produced in fungi, including yeast, and invertebrates from ergosterol in response to ultraviolet radiation. In vertebrates as well as host organisms, vitamin D2 is metabolized first to 25-hydroxyvitamin D2 and subsequently to the active 1,25-dihydroxyvitamin D2. Differences in the metabolism and action of vitamin D2 vs. vitamin D3 in mammals is a current topic of research interest.

Vitamin D

Vitamin D refers to a group of fat-soluble steroid compounds with anti-rickets effect and is called anti-rickets vitamin. It is known currently about at least ten or more sterols substance with vitamin D activity. They are mainly presented in the vegetable oil or yeast ergosterol solid which subject to sunlight or ultraviolet irradiation to generate vitamin D2 which is also called as calciferol or ergocalciferol. Therefore, ergosterol is also called as original vitamin D2; the other is from that the human body can convert the cholesterol to the 7-dihydro-cholesterol to be stored in the skin with the later being able to be converted to vitamin D3 upon sunlight and ultraviolet radiation. Vitamin D3 is also known as cholecalciferol and therefore the 7-dehydrocholesterol is also known as original vitamin D3. Vitamin D2 has a very similar structure with vitamin D3 and both of them are the B ring open-ring derivatives of precursor sterols with the difference of them being laid in a extra double bond and a methyl group in the side chain of vitamin D2. Both vitamin D2 and vitamin D3 are colorless or white crystals and are not foul with the melting point being 115~118 ℃ and 84~85 ℃, respectively. They are insoluble in water and easily soluble in alcohol, ether, acetone, and slightly soluble in vegetable oil. They are unstable in air and sunlight and are easily inactivated in moist air. However, vitamin D3 is relatively more stable than vitamin D2. These two have similar physiological roles in the human body with the major role being maintain the normal metabolism of calcium and phosphorus, promoting the deposition of calcium and phosphorus into the bone and tissue and thus it can be used in prevention and treatment of metabolic bone disease such as rickets and osteomalacia. Vitamin D2 and D3 have the same effects on mammals and cows and pigs. However, vitamin D3 has a ten times stronger activity on poultry (birds) than vitamin D2. Vitamin D deficiency can reduce the intestinal absorption of calcium and cause the decomposition of bone calcium and phosphorus. Young livestock will get osteomalacia and adult animals are prone to osteoporosis. Vitamin D deficiency can also lead to animal sternum and spine deformation and that layers give birth to soft-shell eggs. Because vitamin D control the absorption of calcium, phosphorus, too much absorption of vitamin D in the diet can cause high blood calcium, so that excess calcium can be deposited in the heart, blood vessels, joints, pericardium or intestinal wall, leading to heart failure, joint stiffness or intestines disorders. Sunbathing is the most economical source of getting vitamin D. The ergosterol or 7-dehydrocholesterol can be converted into vitamin D inside animal body upon ultraviolet radiation. The hay, yeast, corn leaves, barley, oats, wheat under sunshine and yeast which has been subject to ultraviolet treatment is a good source of vitamin D. Animal products can directly provide vitamin D for the livestock, such as eggs, milk. Cod liver oil is rich in vitamin D levels. Reared animals and animal with insufficient sunlight need to have their daily feed supplied with additional vitamin D. The above information is edited by the lookchem of Dai Xiongfeng.

Chemical Properties

Different sources of media describe the Chemical Properties of 50-14-6 differently. You can refer to the following data:
1. It is white needle crystal or crystalline powder and is odorless and tasteless. Its melting point is 115-118 ℃ (decomposition), Its specific rotation is [α]20D+102.5°(ethanol). The ethanol solution of this product has maximum absorption at 265nm wavelength. It is soluble in ethanol (1: 2), diethyl ether (1: 2), acetone (1:10) and chloroform (1: 0.7) but insoluble in water. Moreover, it has a lower activity in case of light or oxygen.
2. Ergocalciferol is an odorless white crystalline solid

Uses

Different sources of media describe the Uses of 50-14-6 differently. You can refer to the following data:
1. It can be applied to biochemical studies; its clinical drug belongs to a lipid-soluble vitamin which can promote the intestinal absorption of calcium and phosphorus which plays a role of facilitating the calcification of bone. It is clinically used for prevention and treatment of rickets in children and adult osteomalacia. Vitamin D2 can maintain the normal metabolism of calcium and phosphorus and can also promote the body's absorption of calcium and phosphorus. Upon its deficiency, the children are easy to get rickets. China ruled that it can be applied for strengthening margarine with the usage amount being 125~156 μg/kg; its usage amount in fortified dairy is 63~125μg/kg; the usage amount in strengthening infant and children food used is 50~100μg/kg; the usage amount in strengthening milk or milk beverage is 10~40μg/kg; the maximal allowable usage amount in the strengthening solid drinks and ice cream is 10~20μg/kg. It is mainly applied to the prevention and treatment of rickets, osteomalacia, and infant tetany psychosis.
2. The synthetic form of vitamin D. Prepared from ergosterol by UV irradiation in a suitable solvent. Commercial solutions are usually made with propylene glycol or sesame oil. Antirachitic
3. antirachitic vitamin; LD50 (rat) 56 mg/kg po
4. Rodenticide.
5. Vitamin d2 is fat-soluble, and is stable unless oxidized. It is necessary for growth and maintenance of teeth and bones and the normal utilization of calcium and phosphorus; it is used medicinally in the treatment of rickets and as a dietary supplement. Its sources include fish liver and vitamin d-fortified milk.
6. Vitamin D2 is formed by photochemical cleavage of ergosterin, which is a side-product of many fermentation processes. Microorganisms usually contain up to 3 percent of ergosterin.

Toxicity

Acute toxicity dose: 100 mg/d (adult, orally). Mouse lethal dose of 20mg/kg (6 Day). Excess can easily cause poisoning. GRAS (FDA, §182.5950, 2000). LD50: 42mg/kg (rat, oral).

Limited use

GB 14880-94 (μg/kg): liquid milk from 10 to 20; margarine: 125 to 156; dairy products: 63 to 125; milk and milk drinks: 10 to 40; infant and children food: 50 to 115. GB 2760-2002 (pg/kg): solid drink, ice cream, 10 to 20; arrowroot flour: 50 to 100; Soy milk, soy flour, 15 to 60; soy milk, soy milk, 3 to 15; jelly: 10 to 40; instant breakfast cereals, 12.5 to 37.5; puffed food sandwich from 10 to 60. FDA, §184.1950 (IU/100g; 2001): breakfast cereals 350; 90 granular and pasty products; milk 42; 89 dairy products.

Production method

Dissolve the ergosterol dissolved in ethanol and go through ring-opening under UV illumination; the reaction was further concentrated under reduced pressure, frozen, filtered, and filtered of liquid nitrogen, and concentrated under reduced pressure to dryness to obtain the crude oil of vitamin D2 with distillation to obtain the refined products. Vitamin D2 is naturally presented in the liver, egg yolk and milk; the production method of the industry starts with extracting the ergocalciferol from vegetable oil or yeast extract in the body. Further dissolve it in chloroform or cyclohexane, and then convert it to the vitamin D2 through ultraviolet radiation on the quartz glass flask. Ergosterol ethanol solution is subject to ultraviolet radiation with the 9’, 10’ bond breakage to obtain the vitamin D2 crude product; the later one further has esterification with 3, 5-nitrobenzoyl chloride and undergoes alkaline hydrolysis to get the purified product.

References

https://en.wikipedia.org/wiki/Ergocalciferol https://pubchem.ncbi.nlm.nih.gov/compound/ergocalciferol https://www.drugs.com https://medlineplus.gov https://www.webmd.com

Definition

ChEBI: A vitamin D supplement and has been isolated from alfalfa.

Brand name

Deltalin (Lilly); Drisdol(Sanofi Aventis).

General Description

Odorless white crystals. Used as a dietary supplement and food additive.

Reactivity Profile

Flammable and/or toxic gases are generated by the combination of alcohols with alkali metals, nitrides, and strong reducing agents. They react with oxoacids and carboxylic acids to form esters plus water. Oxidizing agents convert them to aldehydes or ketones. Alcohols exhibit both weak acid and weak base behavior. They may initiate the polymerization of isocyanates and epoxides.

Health Hazard

Vitamin D2 poisoning disturbs calcium metabolism and causes kidney damage. Vitamin D2 in a single acute ingestion presents no toxic hazards. Daily ingestion in excess of 5000 units/day in children or 7500 units/day in adults will produce toxic symptoms associated with hypervitaminosis D. Those with hypercalcemia are at a greater risk.

Fire Hazard

Shows signs of decomposition when stored for a few days at room temperature.

Safety Profile

Poison by ingestion, intraperitoneal, intravenous, and intramuscular routes. An experimental teratogen. Human systemic effects by ingestion: anorexia, nausea or vomiting, and weight loss. Experimental reproductive effects. When heated to decomposition it emits acrid smoke and irritating fumes.

Potential Exposure

Used as a nutrient and/or dietary supplement food additive

Metabolic pathway

Ergocalciferol (vitamin D2) is a product made by the UV irradiation of yeast ergosterol. It is a common form of vitamin D and it has very similar biological activity to that of cholecalciferol (vitamin D3) in the treatment of the vitamin D deficiency diseases (e.g. rickets). The bioactive form of this vitamin is also the 1,25-dihydroxy-derivative and this has equal antirachitic activity to that of the cholecalciferol analogue (Jones et al., 1975).

Purification Methods

It is converted into its 3,5-dinitrobenzoyl ester and crystallised repeatedly from acetone. The ester is then saponified and the free vitamin is isolated. [Laughland & Phillips Anal Chem 28 817 1956, Beilstein 6 IV 4404.]

Degradation

It is unstable in light and air and in acidic media. It is inactivated within a few days under normal exposure conditions. This is due to oxidation and fragmentation of the triene functionality. Ergocalciferol is slightly more unstable, probably because of the additional alkene group in the side chain. One of the several degradation products of ergocalciferol has been identified as the ketone (8, shown in Scheme 1) formed by the loss of the methano-cyclohexanol function (Stewart et al., 1984).

Toxicity evaluation

Excess vitamin D in the form of 1,25-dihydroxycalciferol results in hypercalcemia and hypercalciuria, due to increased calcium absorption, bone demineralization, and hyperphosphatemia.

Incompatibilities

Dust may be combustible and may form explosive mixture with air. Incompatible with oxidizers (chlorates, nitrates, peroxides, permanganates, perchlorates, chlorine, bromine, fluorine, etc.); contact may cause fires or explosions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, and epoxides.

Waste Disposal

Dispose of contents and container to an approved waste disposal plant. All federal, state, and local environmental regulations must be observed. It is inappropriate and possibly dangerous to the environment to dispose of expired or waste drugs and pharmaceuticals by flushing them down the toilet or discarding them to the trash. Household quantities of expired or waste pharmaceuticals may be mixed with wet cat litter or coffeegrounds, double-bagged in plastic, discard in trash. Larger quantities shall carefully take into consideration applicable DEA, EPA, and FDA regulations. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

Check Digit Verification of cas no

The CAS Registry Mumber 50-14-6 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 5 and 0 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 50-14:
(4*5)+(3*0)+(2*1)+(1*4)=26
26 % 10 = 6
So 50-14-6 is a valid CAS Registry Number.
InChI:InChI=1/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/t20-,22+,25-,26+,27-,28+/m0/s1

50-14-6 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (C0005)  Calciferol  >98.0%(HPLC)

  • 50-14-6

  • 1g

  • 485.00CNY

  • Detail
  • TCI America

  • (C0005)  Calciferol  >98.0%(HPLC)

  • 50-14-6

  • 5g

  • 1,610.00CNY

  • Detail
  • TCI America

  • (C0005)  Calciferol  >98.0%(HPLC)

  • 50-14-6

  • 25g

  • 5,380.00CNY

  • Detail
  • Sigma-Aldrich

  • (PHR1238)  Ergocalciferol (Vitamin D2)  pharmaceutical secondary standard; traceable to USP, PhEur and BP

  • 50-14-6

  • PHR1238-500MG

  • 1,024.57CNY

  • Detail
  • Sigma-Aldrich

  • (E0900000)  Ergocalciferol  European Pharmacopoeia (EP) Reference Standard

  • 50-14-6

  • E0900000

  • 1,880.19CNY

  • Detail
  • Sigma-Aldrich

  • (Y0001375)  Ergocalciferol for system suitability  EuropePharmacopoeia (EP) Reference Standard

  • 50-14-6

  • Y0001375

  • 1,880.19CNY

  • Detail
  • Supelco

  • (47768)  Ergocalciferol(D2)  analytical standard

  • 50-14-6

  • 000000000000047768

  • 300.69CNY

  • Detail
  • USP

  • (1239005)  Ergocalciferol  United States Pharmacopeia (USP) Reference Standard

  • 50-14-6

  • 1239005-5X30MG

  • 5,036.85CNY

  • Detail

50-14-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name Vitamin D2

1.2 Other means of identification

Product number -
Other names Doral

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:50-14-6 SDS

50-14-6Synthetic route

(3S,5Z,7E)-3-(3,5-dinitro-benzoyloxy)-9,10-seco-ergosta-5,7,10(19),22t-tetraene
4712-11-2

(3S,5Z,7E)-3-(3,5-dinitro-benzoyloxy)-9,10-seco-ergosta-5,7,10(19),22t-tetraene

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
With sodium hydroxide In ethanol at 20℃; for 0.75h; Inert atmosphere;91%
Ergosterol
57-87-4

Ergosterol

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
Stage #1: Ergosterol In 1,4-dioxane Irradiation;
Stage #2: at 100℃;
23%
With diethyl ether Irradiation.mit UV-Licht (durch aethanol. Xylol-Loesung gefiltert);
Einwirkung elektrischer Entladungen;
diethyl ether
60-29-7

diethyl ether

Ergosterol
57-87-4

Ergosterol

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
mit UV-Licht unter Kuehlung bei Luftausschluss.Irradiation;
diethyl ether
60-29-7

diethyl ether

Ergosterol
57-87-4

Ergosterol

A

Calciferol
50-14-6

Calciferol

B

lumisterol
474-69-1

lumisterol

C

tachysterol
115-61-7

tachysterol

Conditions
ConditionsYield
mit UV-Licht unter Kuehlung bei Luftausschluss.Irradiation;
diethyl ether
60-29-7

diethyl ether

Ergosterol
57-87-4

Ergosterol

A

Calciferol
50-14-6

Calciferol

B

tachysterol
115-61-7

tachysterol

Conditions
ConditionsYield
mit UV-Licht unter Kuehlung bei Luftausschluss.Irradiation;
diethyl ether
60-29-7

diethyl ether

lumisterol
474-69-1

lumisterol

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
UV-Licht.Irradiation;
UV-Licht.Irradiation;
diethyl ether
60-29-7

diethyl ether

tachysterol
115-61-7

tachysterol

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
at 20℃; UV-Licht.Irradiation;
previtamin D2
21307-05-1

previtamin D2

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
With benzene at 60℃; Lichtausschluss;
Multi-step reaction with 2 steps
2: diethyl ether / Irradiation.mit UV-Licht (Magnesium-Funken)
View Scheme
3β-hydroxy-9,10-secoergosta-5(E),7(E),10(19),22(E)-tetraene
51744-66-2

3β-hydroxy-9,10-secoergosta-5(E),7(E),10(19),22(E)-tetraene

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
Irradiation.UV-Licht <λ: >290 nm>;
lumisterol
474-69-1

lumisterol

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
With diethyl ether Irradiation.mit UV-Licht (Magnesium-Funken);
With diethyl ether Irradiation.mit UV-Licht (Magnesium-Funken);
lumisterol
474-69-1

lumisterol

A

Calciferol
50-14-6

Calciferol

B

tachysterol
115-61-7

tachysterol

ethanol
64-17-5

ethanol

Ergosterol
57-87-4

Ergosterol

benzene
71-43-2

benzene

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
mit UV-Licht unter Kuehlung bei Luftausschluss.Irradiation;
ethanol
64-17-5

ethanol

Ergosterol
57-87-4

Ergosterol

benzene
71-43-2

benzene

A

Calciferol
50-14-6

Calciferol

B

lumisterol
474-69-1

lumisterol

C

tachysterol
115-61-7

tachysterol

Conditions
ConditionsYield
mit UV-Licht unter Kuehlung bei Luftausschluss.Irradiation;
ethanol
64-17-5

ethanol

Ergosterol
57-87-4

Ergosterol

benzene
71-43-2

benzene

A

Calciferol
50-14-6

Calciferol

B

tachysterol
115-61-7

tachysterol

Conditions
ConditionsYield
mit UV-Licht unter Kuehlung bei Luftausschluss.Irradiation;
Ergosterol
57-87-4

Ergosterol

benzene
71-43-2

benzene

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
mit UV-Licht unter Kuehlung bei Luftausschluss.Irradiation;
Ergosterol
57-87-4

Ergosterol

benzene
71-43-2

benzene

A

Calciferol
50-14-6

Calciferol

B

lumisterol
474-69-1

lumisterol

C

tachysterol
115-61-7

tachysterol

Conditions
ConditionsYield
mit UV-Licht unter Kuehlung bei Luftausschluss.Irradiation;
Ergosterol
57-87-4

Ergosterol

benzene
71-43-2

benzene

A

Calciferol
50-14-6

Calciferol

B

tachysterol
115-61-7

tachysterol

Conditions
ConditionsYield
mit UV-Licht unter Kuehlung bei Luftausschluss.Irradiation;
previtamin D2
21307-05-1

previtamin D2

benzene
71-43-2

benzene

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
at 60℃; Lichtausschluss;
at 40 - 70℃; Rate constant; Isomerisierung;
3β-hydroxy-9,10-secoergosta-5(E),7(E),10(19),22(E)-tetraene
51744-66-2

3β-hydroxy-9,10-secoergosta-5(E),7(E),10(19),22(E)-tetraene

benzene
71-43-2

benzene

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
Isomerisierung; UV-Licht (λ: >290 nm).Irradiation;
Ergosterol
57-87-4

Ergosterol

A

Calciferol
50-14-6

Calciferol

B

previtamin D2
21307-05-1

previtamin D2

C

lumisterol
474-69-1

lumisterol

D

tachysterol
115-61-7

tachysterol

Conditions
ConditionsYield
With var. irradiation time; the influence of sunlamp emission spectrum on the course of the reaction In ethanol Product distribution; Irradiation;
tert-Butyl-dimethyl-{(S)-4-methylene-3-[2-[(1R,3aS,7aR)-7a-methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-(4E)-ylidene]-eth-(Z)-ylidene]-cyclohexyloxy}-silane

tert-Butyl-dimethyl-{(S)-4-methylene-3-[2-[(1R,3aS,7aR)-7a-methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-(4E)-ylidene]-eth-(Z)-ylidene]-cyclohexyloxy}-silane

A

Calciferol
50-14-6

Calciferol

B

(7Z)-Vitamin D2
247900-07-8

(7Z)-Vitamin D2

Conditions
ConditionsYield
With tetrabutyl ammonium fluoride In tetrahydrofuran at 20℃; desilylation; overnight;
O-(3.5-dinitro-benzoyl)-ergocalciferol
4712-11-2, 116572-06-6, 124564-78-9

O-(3.5-dinitro-benzoyl)-ergocalciferol

ethanolic KOH-solution

ethanolic KOH-solution

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
unter Stickstoff;
O-(3.5-dinitro-benzoyl)-ergocalciferol
4712-11-2, 116572-06-6, 124564-78-9

O-(3.5-dinitro-benzoyl)-ergocalciferol

methanol. KOH-solution

methanol. KOH-solution

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
unter Stickstoff;
O-(Naphthoyl-(2))-ergocalciferol

O-(Naphthoyl-(2))-ergocalciferol

methylammonium carbonate
15719-64-9, 15719-76-3, 97762-63-5

methylammonium carbonate

methanol. KOH-solution

methanol. KOH-solution

Calciferol
50-14-6

Calciferol

(1R,3aR,7aR)-7a-Methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-4-one
55812-80-1, 55870-05-8, 70144-73-9

(1R,3aR,7aR)-7a-Methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-4-one

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1.1: 81 percent / Amberlite<*> IR-118 ion-exchange resin; Na; EtOH / diethyl ether / 2.5 h / 0 °C
2.1: 72 percent / PPh3; diisopropyl azodicarboxylate / tetrahydrofuran / 25 h / 0 - 20 °C
3.1: 73 percent / H2O2 / (NH4)6Mo7O24*4H2O / aq. ethanol / 240 h / 20 °C
4.1: NaHMDS / diethyl ether; tetrahydrofuran / 1 h / -78 °C
4.2: Dess-Martin periodinane / CH2Cl2 / 0.5 h / 20 °C
4.3: diethyl ether; tetrahydrofuran / -100 - 20 °C
5.1: Bu4NF*3H2O / tetrahydrofuran / 20 °C / overnight
View Scheme
(2Z)-2-<(5S)-5-(tert-butyldimethylsilyloxy)-2-methylene-cyclohexylidene>-ethanol
96685-53-9

(2Z)-2-<(5S)-5-(tert-butyldimethylsilyloxy)-2-methylene-cyclohexylidene>-ethanol

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: NaHMDS / diethyl ether; tetrahydrofuran / 1 h / -78 °C
1.2: Dess-Martin periodinane / CH2Cl2 / 0.5 h / 20 °C
1.3: diethyl ether; tetrahydrofuran / -100 - 20 °C
2.1: Bu4NF*3H2O / tetrahydrofuran / 20 °C / overnight
View Scheme
(4R,7aR)-1-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-4-((R,Z)-1-hydroxy-2-((S)-5-hydroxy-2-methylenecyclohexylidene)ethyl)-7a-methyloctahydro-1H-inden-4-ol
84985-78-4

(4R,7aR)-1-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-4-((R,Z)-1-hydroxy-2-((S)-5-hydroxy-2-methylenecyclohexylidene)ethyl)-7a-methyloctahydro-1H-inden-4-ol

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1.1: 89 percent / imidazole; DMAP / CH2Cl2 / 20 °C
2.1: pyridine; Pb(OAc)4 / CH2Cl2 / 0.25 h / 0 °C
2.2: 83 percent / CeCl3*7H2O; NaBH4 / methanol / 0.25 h / 0 °C
3.1: 81 percent / Amberlite<*> IR-118 ion-exchange resin; Na; EtOH / diethyl ether / 2.5 h / 0 °C
4.1: 72 percent / PPh3; diisopropyl azodicarboxylate / tetrahydrofuran / 25 h / 0 - 20 °C
5.1: 73 percent / H2O2 / (NH4)6Mo7O24*4H2O / aq. ethanol / 240 h / 20 °C
6.1: NaHMDS / diethyl ether; tetrahydrofuran / 1 h / -78 °C
6.2: Dess-Martin periodinane / CH2Cl2 / 0.5 h / 20 °C
6.3: diethyl ether; tetrahydrofuran / -100 - 20 °C
7.1: Bu4NF*3H2O / tetrahydrofuran / 20 °C / overnight
View Scheme
Multi-step reaction with 4 steps
1.1: 89 percent / imidazole; DMAP / CH2Cl2 / 20 °C
2.1: pyridine; Pb(OAc)4 / CH2Cl2 / 0.25 h / 0 °C
2.2: 81 percent / CeCl3*7H2O; NaBH4 / methanol / 0.25 h / 0 °C
3.1: NaHMDS / diethyl ether; tetrahydrofuran / 1 h / -78 °C
3.2: Dess-Martin periodinane / CH2Cl2 / 0.5 h / 20 °C
3.3: diethyl ether; tetrahydrofuran / -100 - 20 °C
4.1: Bu4NF*3H2O / tetrahydrofuran / 20 °C / overnight
View Scheme
(5Z,22E)-(7R)-3β-(tert-butyldimethylsilyloxy)-9,10-seco-8α-ergosta-5,10(19),22-triene-7,8-diol
131852-63-6

(5Z,22E)-(7R)-3β-(tert-butyldimethylsilyloxy)-9,10-seco-8α-ergosta-5,10(19),22-triene-7,8-diol

Calciferol
50-14-6

Calciferol

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1.1: pyridine; Pb(OAc)4 / CH2Cl2 / 0.25 h / 0 °C
1.2: 83 percent / CeCl3*7H2O; NaBH4 / methanol / 0.25 h / 0 °C
2.1: 81 percent / Amberlite<*> IR-118 ion-exchange resin; Na; EtOH / diethyl ether / 2.5 h / 0 °C
3.1: 72 percent / PPh3; diisopropyl azodicarboxylate / tetrahydrofuran / 25 h / 0 - 20 °C
4.1: 73 percent / H2O2 / (NH4)6Mo7O24*4H2O / aq. ethanol / 240 h / 20 °C
5.1: NaHMDS / diethyl ether; tetrahydrofuran / 1 h / -78 °C
5.2: Dess-Martin periodinane / CH2Cl2 / 0.5 h / 20 °C
5.3: diethyl ether; tetrahydrofuran / -100 - 20 °C
6.1: Bu4NF*3H2O / tetrahydrofuran / 20 °C / overnight
View Scheme
Multi-step reaction with 3 steps
1.1: pyridine; Pb(OAc)4 / CH2Cl2 / 0.25 h / 0 °C
1.2: 81 percent / CeCl3*7H2O; NaBH4 / methanol / 0.25 h / 0 °C
2.1: NaHMDS / diethyl ether; tetrahydrofuran / 1 h / -78 °C
2.2: Dess-Martin periodinane / CH2Cl2 / 0.5 h / 20 °C
2.3: diethyl ether; tetrahydrofuran / -100 - 20 °C
3.1: Bu4NF*3H2O / tetrahydrofuran / 20 °C / overnight
View Scheme
Calciferol
50-14-6

Calciferol

(S)-3-[(1R,3aS,7aR)-7a-Methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-(4E)-ylidenemethyl]-2,2-dioxo-2,3,4,5,6,7-hexahydro-1H-2λ6-benzo[c]thiophen-5-ol
87680-65-7

(S)-3-[(1R,3aS,7aR)-7a-Methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-(4E)-ylidenemethyl]-2,2-dioxo-2,3,4,5,6,7-hexahydro-1H-2λ6-benzo[c]thiophen-5-ol

Conditions
ConditionsYield
With sulfur dioxide 1.) reflux, 30 min, 2.) RT, 30 min;100%
With sulfur dioxide In water; benzene for 3.5h;
With sulfur dioxide In dichloromethane at -10℃; for 1.25h;
Calciferol
50-14-6

Calciferol

(8S,20S)-de-A,B-20-(hydroxymethyl)pregnan-8-ol
64190-52-9

(8S,20S)-de-A,B-20-(hydroxymethyl)pregnan-8-ol

Conditions
ConditionsYield
Stage #1: Calciferol With ozone In methanol; dichloromethane at -78℃; for 3h; Inert atmosphere;
Stage #2: With sodium tetrahydroborate In methanol; dichloromethane at -78 - 20℃; for 0.5h; Inert atmosphere;
99%
Stage #1: Calciferol With ozone In dichloromethane at -78℃;
Stage #2: With sodium tetrahydroborate In methanol at 0℃;
90%
Stage #1: Calciferol With pyridine; ozone In methanol at -78℃; Inert atmosphere;
Stage #2: With methanol; sodium tetrahydroborate at 20℃;
81%
Calciferol
50-14-6

Calciferol

p-toluenesulfonyl chloride
98-59-9

p-toluenesulfonyl chloride

vitamin D2 tosylate
72204-99-0

vitamin D2 tosylate

Conditions
ConditionsYield
With pyridine99%
With triethylamine In dichloromethane at -5 - 20℃;89.4%
With pyridine at 20 - 22℃; for 22h;
Calciferol
50-14-6

Calciferol

C28H46O3S

C28H46O3S

Conditions
ConditionsYield
With sulfur dioxide In dichloromethane at -20 - -10℃; Inert atmosphere;95.7%
Calciferol
50-14-6

Calciferol

tert-butyldimethylsilyl chloride
18162-48-6

tert-butyldimethylsilyl chloride

3(S)-tert-butyldimethylsilyloxy-9,10-secoergosta-5,7(E),10(19),22(E)-tetraene
104846-62-0

3(S)-tert-butyldimethylsilyloxy-9,10-secoergosta-5,7(E),10(19),22(E)-tetraene

Conditions
ConditionsYield
With 1H-imidazole In N,N-dimethyl-formamide for 2.5h;95%
With 1H-imidazole In N,N-dimethyl-formamide at 20℃; for 1h;92%
With 1H-imidazole In N,N-dimethyl-formamide at 20℃; for 1h;92%
poly(methacrylic acid)
79-41-4

poly(methacrylic acid)

Calciferol
50-14-6

Calciferol

vitamin D2 methacrylate

vitamin D2 methacrylate

Conditions
ConditionsYield
With dmap In diethyl ether at 50℃;95%
chloro-trimethyl-silane
75-77-4

chloro-trimethyl-silane

Calciferol
50-14-6

Calciferol

vitamin D2 trimethylsilyl ether
2754-48-5

vitamin D2 trimethylsilyl ether

Conditions
ConditionsYield
With 1,1,1,3,3,3-hexamethyl-disilazane In tetrahydrofuran for 0.5h; Heating;94%
succinic acid anhydride
108-30-5

succinic acid anhydride

Calciferol
50-14-6

Calciferol

ergocalciferol hemisuccinate
1373140-59-0

ergocalciferol hemisuccinate

Conditions
ConditionsYield
With triethylamine In dichloromethane at 20℃; for 24h; Inert atmosphere; Darkness;93%
With pyridine
Calciferol
50-14-6

Calciferol

A

10(R),19-dihydrovitamin D2
807-27-2

10(R),19-dihydrovitamin D2

B

10(S),19-dihydrovitamin D2
65377-86-8

10(S),19-dihydrovitamin D2

Conditions
ConditionsYield
With bis(cyclopentadienyl)titanium dichloride; lithium aluminium tetrahydride In tetrahydrofuran for 2.5h;A 10%
B 90%
With bis(cyclopentadienyl)titanium dichloride; sodium bis(2-methoxyethoxy)aluminium dihydride In tetrahydrofuran; toluene for 1.5h; Product distribution; Ambient temperature; var. reducing agents, ratios of reagents, solvents, and reaction time; other analogues of vitamin D2;A 60%
B 40%
With bis(cyclopentadienyl)titanium dichloride In tetrahydrofuran; toluene for 1.5h; Ambient temperature;A 60%
B 40%
Calciferol
50-14-6

Calciferol

1,1'-carbonyldiimidazole
530-62-1

1,1'-carbonyldiimidazole

Imidazole-1-carboxylic acid (S)-4-methylene-3-[2-[(1R,3aS,7aR)-7a-methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-(4E)-ylidene]-eth-(Z)-ylidene]-cyclohexyl ester
286949-85-7

Imidazole-1-carboxylic acid (S)-4-methylene-3-[2-[(1R,3aS,7aR)-7a-methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-(4E)-ylidene]-eth-(Z)-ylidene]-cyclohexyl ester

Conditions
ConditionsYield
With triethylamine In dichloromethane for 2h; Condensation; Heating;90%
Calciferol
50-14-6

Calciferol

ercalcidiol
21343-40-8

ercalcidiol

Conditions
ConditionsYield
With dihydrogen peroxide In aq. phosphate buffer at 40℃; for 1h; pH=7; Enzymatic reaction; regioselective reaction;90%
With NADPH; NADPH-P450 reductase In various solvent(s) at 37℃; pH=7.7; Enzyme kinetics;
With coprinopsis cinerea peroxygenase; dihydrogen peroxide In aq. phosphate buffer; acetone at 40℃; for 1h; pH=7; Reagent/catalyst; Enzymatic reaction;
4-Phenyl-1,2,4-triazolidine-3,5-dione
4233-33-4

4-Phenyl-1,2,4-triazolidine-3,5-dione

Calciferol
50-14-6

Calciferol

6(S),19-(4-phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl)-3β-hydroxy-9,10-secoergosta-5(10),7(E),22(E)-triene
104973-27-5

6(S),19-(4-phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl)-3β-hydroxy-9,10-secoergosta-5(10),7(E),22(E)-triene

Conditions
ConditionsYield
In ethyl acetate at 0℃; for 1h;86%
2-oxo-2H-chromene-3-carboxylic acid
531-81-7

2-oxo-2H-chromene-3-carboxylic acid

Calciferol
50-14-6

Calciferol

C38H48O4

C38H48O4

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane for 0.25h; Inert atmosphere; Microwave irradiation;85%
6-bromocoumarin-3-carboxylic acid
2199-87-3

6-bromocoumarin-3-carboxylic acid

Calciferol
50-14-6

Calciferol

C38H47BrO4

C38H47BrO4

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane for 0.25h; Inert atmosphere; Microwave irradiation;84%
7-methyl-2-oxo-2H-chromene-3-carboxylic acid
1049115-94-7

7-methyl-2-oxo-2H-chromene-3-carboxylic acid

Calciferol
50-14-6

Calciferol

C39H50O4

C39H50O4

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane for 0.25h; Inert atmosphere; Microwave irradiation;83%
6-chloro-2-oxo-2H-chromene-3-carboxylic acid
883-92-1

6-chloro-2-oxo-2H-chromene-3-carboxylic acid

Calciferol
50-14-6

Calciferol

C38H47ClO4

C38H47ClO4

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane for 0.25h; Inert atmosphere; Microwave irradiation;81%
Calciferol
50-14-6

Calciferol

(1R,3aR,7aR)-7a-Methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-4-one
55812-80-1, 55870-05-8, 70144-73-9

(1R,3aR,7aR)-7a-Methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-4-one

Conditions
ConditionsYield
Stage #1: Calciferol With potassium permanganate In ethanol; water at -15℃;
Stage #2: With pyridine; lead(IV) tetraacetate In dichloromethane at -15℃;
80%
Product distribution; Ambient temperature; degradation;
With potassium permanganate; sulfuric acid; benzene
Calciferol
50-14-6

Calciferol

C13H24O2

C13H24O2

Conditions
ConditionsYield
Stage #1: Calciferol With ozone
Stage #2: With sodium tetrahydroborate In methanol at -78℃;
80%
Calciferol
50-14-6

Calciferol

6,8-dichlorocoumarin-3-carboxylic acid
2199-86-2

6,8-dichlorocoumarin-3-carboxylic acid

C38H46Cl2O4

C38H46Cl2O4

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane for 0.25h; Inert atmosphere; Microwave irradiation;80%
1-oxyl-4-carboxyl-2,2,6,6-tetramethylpiperidine
37149-18-1

1-oxyl-4-carboxyl-2,2,6,6-tetramethylpiperidine

Calciferol
50-14-6

Calciferol

(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexanyl 2,2,6,6-tetra-methylpiperidine-1-oxyl-4-carboxylate

(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexanyl 2,2,6,6-tetra-methylpiperidine-1-oxyl-4-carboxylate

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 0 - 20℃; for 26h; Inert atmosphere;76%
Calciferol
50-14-6

Calciferol

(1R,3aR,7aR)-1-((S)-1-hydroxypropan-2-yl)-7a-methyloctahydro-1H-inden-4-ol
185997-26-6

(1R,3aR,7aR)-1-((S)-1-hydroxypropan-2-yl)-7a-methyloctahydro-1H-inden-4-ol

Conditions
ConditionsYield
With sodium tetrahydroborate; ozone In methanol; dichloromethane at -78℃;75%
Stage #1: Calciferol With sodium hydrogencarbonate; ozone In methanol; dichloromethane at -78℃;
Stage #2: With sodium tetrahydroborate In methanol; dichloromethane at -78 - 0℃;
60%
Stage #1: Calciferol With sodium hydrogencarbonate; ozone In methanol; dichloromethane at 20℃;
Stage #2: With sodium tetrahydroborate
50%
With ozone
Multi-step reaction with 2 steps
1: ozonolysis
2: sodium tetrahydroborate
View Scheme
Calciferol
50-14-6

Calciferol

1-(1-hydroxypropan-2-yl)-7α-methyloctahydro-1H-inden-4-ol

1-(1-hydroxypropan-2-yl)-7α-methyloctahydro-1H-inden-4-ol

Conditions
ConditionsYield
Stage #1: Calciferol With sodium hydrogencarbonate In methanol; dichloromethane at -78℃; Inert atmosphere;
Stage #2: With ozone In methanol; dichloromethane for 48h;
Stage #3: With methanol; sodium tetrahydroborate In dichloromethane at 20℃;
75%
Calciferol
50-14-6

Calciferol

acetic anhydride
108-24-7

acetic anhydride

ergocalciferol acetate
2579-08-0

ergocalciferol acetate

Conditions
ConditionsYield
With trimethylsilyl trifluoromethanesulfonate In dichloromethane at 0℃; for 0.0833333h;71%
With trimethylsilyl trifluoromethanesulfonate In dichloromethane at 0℃; for 0.0833333h;71%
Calciferol
50-14-6

Calciferol

(4R,7aR)-1-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-4-((R,Z)-1-hydroxy-2-((S)-5-hydroxy-2-methylenecyclohexylidene)ethyl)-7a-methyloctahydro-1H-inden-4-ol
84985-78-4

(4R,7aR)-1-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-4-((R,Z)-1-hydroxy-2-((S)-5-hydroxy-2-methylenecyclohexylidene)ethyl)-7a-methyloctahydro-1H-inden-4-ol

Conditions
ConditionsYield
With potassium permanganate70%
With potassium permanganate In ethanol at -20℃; for 2h;65%
With potassium permanganate In ethanol; water at -30 - 45℃;1.9 g
With potassium permanganate
With potassium permanganate In ethanol; water at -45 - 20℃; for 4.5h; regioselective reaction;
Calciferol
50-14-6

Calciferol

[1S-[1β(R*),3aα,7aβ]]-octahydro-1-(2-hydroxy-1-methylethyl)-7a-methyl-4H-inden-4-one
79918-70-0

[1S-[1β(R*),3aα,7aβ]]-octahydro-1-(2-hydroxy-1-methylethyl)-7a-methyl-4H-inden-4-one

Conditions
ConditionsYield
Stage #1: Calciferol With ozone In methanol; dichloromethane at -70℃;
Stage #2: With sodium tetrahydroborate In methanol; dichloromethane
68%
Multi-step reaction with 3 steps
1: acetonitrile
2: ruthenium trichloride; sodium periodate / acetonitrile; ethyl acetate; water
3: ruthenium trichloride; sodium periodate / acetonitrile; ethyl acetate; water
View Scheme
Calciferol
50-14-6

Calciferol

(3S,5Z,7Ξ)-9,10-seco-8ξ-ergosta-5,10(19),22t-triene-3,7,8-triol
84985-78-4, 54661-20-0

(3S,5Z,7Ξ)-9,10-seco-8ξ-ergosta-5,10(19),22t-triene-3,7,8-triol

Conditions
ConditionsYield
With potassium permanganate In ethanol; water at -20 - 40℃; for 0.75h;65%
With potassium permanganate In tetrahydrofuran; water65%
With potassium permanganate In ethanol at -30 - 45℃; for 4.16667h;62.7%
With potassium permanganate In ethanol; water40.4%
With potassium permanganate
Calciferol
50-14-6

Calciferol

chlorophosphoric acid diphenyl ester
2524-64-3

chlorophosphoric acid diphenyl ester

ergocalciferol diphenyl phosphate

ergocalciferol diphenyl phosphate

Conditions
ConditionsYield
With titanium(IV) tetrabutoxide; triethylamine In dichloromethane at 20℃; for 20h;63%

50-14-6Relevant articles and documents

-

Windaus,Luettringhaus,Deppe

, p. 252,265 (1931)

-

-

Windaus,Luettringhaus

, p. 70,75 (1931)

-

Production process of vitamin D2

-

Paragraph 0026; 0027; 0028; 0029; 0030; 0031; 0032; 0033, (2017/05/19)

The invention discloses a production process of vitamin D2. The process includes the steps of: S1) light irradiation and thermal-isomerization reaction; S2) chromatographic eluting separation; S3) freezing crystallization separation; S4) drying, mixing and packaging. Compared with the prior art, the process is modified in synthetic process conditions, so that the process is improved in productivity and total yield of the product reaches more than 90%. The thermal-isomerization reaction and a pressure-reduced concentration step are combined, so that the process is simplified and is reduced in energy consumption. A synthesis reaction zone and a purifying separation zone are completely separated, so that process maintenance and process management are convenient. In addition, in the purifying process, a chromatographic crystallization method is employed directly instead of a process comprising chromatography, esterification and hydrolytic crystallization in the prior art, so that usage of toxic organic reagents is avoided, and the process is energy-saving, reduces consumption and is environment-friendly. In the production process of the vitamin D2, tail oil and tail materials contain lumisterol, tachysterol and other derivative products, so that it is valuable to deeply research and develop a high-value medicine intermediate.

(20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses

-

, (2008/06/13)

The compound (20S)-1α-hydroxy-2 methylene-19 nor-vitamin D3 and pharmaceutical uses therefor are described herein. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the tretment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has very significant calcemic activity and therefore may be used to treat immune disorders in humans as well as metabolic bone diseases such as osteoporosis.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 50-14-6